



## **Anergis to Present Three Scientific Posters at 34th European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015**

EPALINGES, Switzerland, June 4, 2015 – Anergis, a company developing novel and proprietary ultra-fast allergy immunotherapeutics, will present three scientific posters at the 34<sup>th</sup> European Academy of Allergy and Clinical Immunology (EAACI) Congress 2015 (Barcelona, June 6-10, 2015). All posters will focus on Anergis' birch pollen immunotherapeutic AllerT, featuring detailed clinical data as well as in vitro and in vivo safety and immunogenicity data. AllerT is Anergis' most advanced product and based on the company's proprietary Contiguous Overlapping Peptide (COP) platform.

The following scientific communications will be presented at the EAACI Conference 2015:

**Presentation Title:** *"Phase IIb follow-up trial of sustained efficacy of AllerT allergy vaccine during a second birch pollen season"*

**Presenter:** Gilles Della Corte

**Time and Date:** Sunday, June 7, 2015, at 02:06pm CET

**Session:** Oral Abstract Session OAS 10 AIT: Efficacy and clinical outcomes

**Abstract #:** 327

**Presentation Title:** *"Persistence of anti-Bet v 1 IgG4 prior and during a second pollen season after AllerT ultra-fast immunotherapy (phase IIb follow up)"*

**Presenter:** Dr. Christophe Reymond

**Time and Date:** Tuesday, June 9, 2015, at 10:30am CET

**Session:** Poster Discussion Session PDS 25: Immunotherapy vaccines

**Abstract #:** 530

**Presentation Title:** *"Requirement for aluminium hydroxide as adjuvant for successful ultra-fast immunotherapy with AllerT"*

**Presenter:** Dr. Alexander Kettner



**Time and Date:** Monday, June 8, 2015, at 12:00pm CET

**Session:** Thematic Poster Session TPS 32: Allergen standardization

**Abstract #:** 1141

###

### **About Anergis**

Anergis SA is a Swiss-based biopharmaceutical company specializing in the discovery and development of novel, proprietary allergy immunotherapeutics that target commercially attractive indications. Anergis' long-peptide immunotherapeutics are based on its IP-protected Contiguous Overlapping Peptide (COP) technology. Allergies are the most prevalent and fastest growing chronic conditions in the industrialized world affecting over 500 million people.

Anergis' lead-product AllerT for patients with birch pollen allergy is due to enter Phase III clinical development. Two additional allergy immunotherapy product candidates against ragweed pollen allergy (AllerR) and house dust mite allergy (AllerDM) are in preclinical development and expected to reach clinical testing in 2016/2017.

Anergis has raised CHF 47 million to date from private and institutional investors, including BioMedInvest, Renaissance PME, Sunstone Capital, and WJFS, Inc.

### **About Anergis' COP Technology**

The only curative therapy of allergies available today, known as "desensitization" or conventional "Allergy Immunotherapy" (AIT), is the process of inducing tolerance to the allergen. It requires 3-5 years of treatment and exposes patients to the risk of immediate (<30 min) anaphylactic reactions which can be life-threatening. With its ultra-fast COP allergy immunotherapy, Anergis is shaping the future of allergy treatment. Anergis' long-peptide immunotherapeutics are based on COPs which reproduce the complete amino acid sequence of the allergen in separate synthetic long peptides. COP allergy immunotherapeutics do not cross-react with IgE, the antibody class responsible for eliciting allergic hypersensitivity. Therefore, COPs can be administered safely independent of MHC restriction and at high doses to induce tolerance to the allergen



after only a few injections. This enables desensitization in 2 months as opposed to 3 years. Studies of COPs targeting bee venom and birch pollen allergies in both animals and humans have established the proof-of-concept of Anergis COP allergy immunotherapeutics in terms of safety (i.e. no immediate allergic reaction), immunogenicity (production of specific antibodies and cytokines against the original allergen and establishment of a long-term immune memory) and clinical efficacy (reduction of clinical allergy symptoms during at least two natural pollen seasons) after a single 2-month course of treatment.

**Contact:**

Anergis SA  
CH-1066 Epalinges  
Vincent Charlon, CEO  
[info@anergis.ch](mailto:info@anergis.ch)

**Media Inquiries:**

akampion  
Dr. Ludger Wess, Ines-Regina Buth  
Managing Partners  
Tel. +49 40 88165964 or +49 30 2363 2768  
[info@akampion.com](mailto:info@akampion.com)